Group 1 - Madrigal Pharmaceuticals has emerged as a significant player in the treatment of metabolic liver diseases with its drug Rezdiffra (resmetirom), which is indicated for F2-F3 MASH [1] - Rezdiffra has received accelerated approval in the US and is demonstrating blockbuster potential in the market [1]